| 000 | 01514 a2200397 4500 | ||
|---|---|---|---|
| 005 | 20250513160159.0 | ||
| 264 | 0 | _c19990122 | |
| 008 | 199901s 0 0 eng d | ||
| 022 | _a0008-6363 | ||
| 024 | 7 |
_a10.1016/s0008-6363(98)00155-2 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRabelink, T J | |
| 245 | 0 | 0 |
_aEndothelin blockers and renal protection: a new strategy to prevent end-organ damage in cardiovascular disease? _h[electronic resource] |
| 260 |
_bCardiovascular research _cSep 1998 |
||
| 300 |
_a543-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAngiotensin-Converting Enzyme Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAspartic Acid Endopeptidases _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aCardiovascular Diseases _xcomplications |
| 650 | 0 | 4 |
_aDiabetic Nephropathies _xmetabolism |
| 650 | 0 | 4 | _aEndothelin Receptor Antagonists |
| 650 | 0 | 4 |
_aEndothelin-1 _xmetabolism |
| 650 | 0 | 4 | _aEndothelin-Converting Enzymes |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aHemodynamics _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aKidney Failure, Chronic _xetiology |
| 650 | 0 | 4 | _aMetalloendopeptidases |
| 650 | 0 | 4 |
_aRenin-Angiotensin System _xdrug effects |
| 700 | 1 | _aStroes, E S | |
| 700 | 1 | _aBouter, K P | |
| 700 | 1 | _aMorrison, P | |
| 773 | 0 |
_tCardiovascular research _gvol. 39 _gno. 3 _gp. 543-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0008-6363(98)00155-2 _zAvailable from publisher's website |
| 999 |
_c9824084 _d9824084 |
||